跳至主要内容
临床试验/NCT05093101
NCT05093101已完成不适用

The Prognostic Value of Serum Biomarkers in Osteosarcoma

Istituto Ortopedico Rizzoli1 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2021年7月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
600
试验地点
1
主要终点
Evaluation of 5-year survival

研究概览

简要总结

Observational retrospective cohort study using laboratory data of blood tests prior to surgical and chemotherapy treatment and other histologic, clinical, and instrumental data related to patient history from digitized medical records and analysis of the same as predictors of outcomes.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
2 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Osteosarcoma diagnosed at the Pathological Anatomy of the Rizzoli Orthopaedic Institute in Bologna;
  • Minimum 2-year follow-up period;
  • Medical records, complete blood work and instrumental examinations, regular follow-up;
  • Patients with age ≥ 2 years;

排除标准

  • Patients with osteosarcoma who have received medical treatment (surgery, radiotherapy or chemotherapy) in other hospitals prior to admission to our Institute

结局指标

主要结局

Evaluation of 5-year survival

时间窗: 5 years

Evaluation of 5-year survival in relation to histologic, laboratory, clinical, and instrumental prognostic factors

次要结局

  • Evaluation of the rate of local recurrence(5 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Costantino Errani

Principal Investigator

Istituto Ortopedico Rizzoli

研究点 (1)

Loading locations...

相似试验